XERS
$11.13+1.64%
Xeris Biopharma Holdings Inc.Stock · HealthcareRussell 2000 · 0.04% of IWMRussell 3000 · 0.002% of IWVUS Stock Market · 0.002% of VTI
XERS financial statements
The full income statement, balance sheet, and cash-flow statement for Xeris Biopharma Holdings Inc. (XERS), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 149.0M2024-09 149.1M2024-12 153.9M2025-03 160.2M2025-06 161.5M2025-09 165.9M2025-12 172.4M2026-03 172.6M2026-06 182.3M+22.4% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 292M+43.7% | 203M+23.9% | 164M+48.7% | 110M+122.3% | 49.6M+146.0% | |
| Research & development | 31.2M+21.9% | 25.6M+14.4% | 22.3M+6.6% | 21.0M-16.7% | 25.2M+20.3% | |
| Selling, general & administrative | 182M+11.6% | 163M+11.9% | 146M+6.1% | 138M+9.6% | 126M+70.5% | |
| Amortization of intangibles | 10.8M+0.0% | 10.8M+0.0% | 10.8M+0.0% | 10.8M+1871.5% | 550K | |
| Operating income | 24.9M+174.0% | -33.6M+23.5% | -44.0M+46.3% | -81.9M+28.8% | -115M-37.8% | |
| Interest expense | 29.1M-4.6% | 30.5M+14.6% | 26.6M+88.7% | 14.1M+96.4% | 7.18M-32.6% | |
| Other non-operating income | -24.3M-3.8% | -23.5M-20.3% | -19.5M-37.8% | -14.1M-86.9% | -7.57M+1.8% | |
| Pre-tax income | 554K+101.0% | -57.1M+10.1% | -63.5M+33.9% | -96.1M+21.7% | -123M | |
| Income tax | 0.00+100.0% | -2.27M-81.6% | -1.25M+12.3% | -1.42M | 0.00+100.0% | |
| 554K+101.0% | -54.8M+11.9% | -62.3M+34.2% | -94.7M+22.9% | -123M-34.7% | ||
| Net income to common | 554K+101.0% | -54.8M+11.9% | -62.3M | — | — | |
| $0.00+100.0% | -$0.37+17.8% | -$0.45+35.7% | -$0.70+54.8% | -$1.55 | ||
| EPS (basic) | $0.00+100.0% | -$0.37+17.8% | -$0.45+35.7% | -$0.70+54.8% | -$1.55 | |
| Weighted-avg shares (basic) | 160M+9.3% | 147M+6.6% | 138M+1.5% | 136M+71.6% | 79.0M | |
| Weighted-avg shares (diluted) | 173M+17.7% | 147M+6.6% | 138M+1.5% | 136M+71.6% | 79.0M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 240M+43.3% | 168M+7.3% | 156M-16.4% | 187M+31.0% | 143M-6.3% | ||
| Cash & equivalents | 111M+55.0% | 71.6M+6.2% | 67.4M-44.7% | 122M+81.3% | 67.3M+78.9% | |
| Short-term investments | — | 0.00-100.0% | 5.00M | 0.00-100.0% | 35.2M-63.4% | |
| Accounts receivable | 51.0M+26.3% | 40.4M+3.1% | 39.2M+27.1% | 30.8M+76.6% | 17.5M+153.9% | |
| Inventory | 68.7M+42.5% | 48.2M+24.0% | 38.8M+57.0% | 24.7M+36.5% | 18.1M+116.9% | |
| Prepaid expenses | 9.55M+28.1% | 7.45M+29.0% | 5.78M-37.8% | 9.29M+102.4% | 4.59M+43.6% | |
| 384M+18.7% | 323M+0.1% | 323M-6.4% | 345M+13.2% | 304M+91.2% | ||
| Property, plant & equipment | 4.95M-11.1% | 5.56M-6.8% | 5.97M+8.2% | 5.52M-16.8% | 6.63M-1.2% | |
| Operating lease right-of-use | 22.1M-2.4% | 22.6M-2.4% | 23.2M+481.3% | 3.99M | 0.00 | |
| Goodwill | 22.9M+0.0% | 22.9M+0.0% | 22.9M+0.0% | 22.9M+0.0% | 22.9M | |
| Intangible assets | 88.1M-11.0% | 98.9M-9.9% | 110M-9.0% | 121M-8.2% | 131M | |
| Other non-current assets | 5.22M-3.5% | 5.41M+19.1% | 4.54M-4.0% | 4.73M+470.6% | 829K+257.3% | |
| 110M+9.1% | 100M+5.5% | 95.2M+29.3% | 73.6M-6.9% | 79.0M+180.2% | ||
| Accounts payable | 3.08M+34.3% | 2.29M-80.2% | 11.6M+151.1% | 4.61M-48.4% | 8.92M+186.3% | |
| Accrued liabilities | 33.2M+19.6% | 27.7M+17.9% | 23.5M-36.1% | 36.8M-25.1% | 49.1M+208.8% | |
| Short-term & current debt | 0.00-100.0% | 15.1M | 0.00 | — | — | |
| Current lease liability | 6.23M+2.5% | 6.08M+74.0% | 3.50M+121.2% | 1.58M | 0.00 | |
| Other current liabilities | 4.89M+348.9% | 1.09M-6.7% | 1.17M-56.1% | 2.66M+33.8% | 1.99M+517.1% | |
| 370M+4.9% | 353M+7.1% | 329M+10.0% | 299M+43.1% | 209M+66.8% | ||
| Long-term debt | 220M+1.5% | 217M+13.7% | 191M+2.1% | 187M+112.4% | 88.1M+1.2% | |
| Non-current lease liability | 31.5M-5.2% | 33.3M-4.3% | 34.8M+269.8% | 9.40M | 0.00 | |
| Operating lease liability (total) | 37.8M-4.0% | 39.3M+2.8% | 38.3M+248.4% | 11.0M | — | |
| Deferred tax liabilities | — | 0.00-100.0% | 2.27M-35.5% | 3.52M-28.8% | 4.94M | |
| Other non-current liabilities | 8.40M+326.9% | 1.97M-59.4% | 4.85M+15538.7% | 31.0K-98.2% | 1.68M-52.6% | |
| 13.7M+146.2% | -29.6M-336.7% | -6.78M-115.0% | 45.2M-52.6% | 95.2M+182.1% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 17.0K+13.3% | 15.0K+7.1% | 14.0K+0.0% | 14.0K+7.7% | 13.0K+116.7% | |
| Additional paid-in capital | 685M+6.7% | 642M+5.2% | 610M+1.7% | 600M+8.0% | 555M+49.6% | |
| Retained earnings | -671M+0.1% | -672M-8.9% | -617M-11.2% | -555M-20.6% | -460M-36.4% | |
| Accumulated other comprehensive income | -25.0K+0.0% | -25.0K+0.0% | -25.0K-8.7% | -23.0K+25.8% | -31.0K-616.7% | |
| Total liabilities & equity | 384M+18.7% | 323M+0.1% | 323M-6.4% | 345M+13.2% | 304M+91.2% | |
| Common shares issued | 166M+11.2% | 149M+8.2% | 138M+1.4% | 136M+9.1% | 125M+109.5% | |
| Common shares outstanding | 166M+11.2% | 149M+8.2% | 138M+1.4% | 136M+9.1% | 125M+109.5% | |
| Shares outstanding (cover) | 172M+12.0% | 154M+9.6% | 140M+2.3% | 137M+1.3% | 136M+126.8% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 28.6M+177.4% | -37.0M+21.4% | -47.0M+54.3% | -103M-7.7% | -95.5M-18.6% | ||
| Depreciation & amortization | 1.31M+7.0% | 1.23M-17.5% | 1.49M+6.3% | 1.40M+5.3% | 1.33M-9.4% | |
| Intangible amortization | 10.8M+0.0% | 10.8M+0.0% | 10.8M+0.0% | 10.8M+1871.5% | 550K | |
| Share-based compensation | 22.4M+21.8% | 18.4M+71.4% | 10.7M-11.9% | 12.2M+6.8% | 11.4M+37.6% | |
| Deferred income taxes | 0.00+100.0% | -2.27M-81.6% | -1.25M+12.3% | -1.42M | 0.00 | |
| Change in receivables | 10.6M+773.2% | 1.22M-85.4% | 8.37M-37.4% | 13.4M+114.4% | 6.24M+185.8% | |
| Change in inventory | 19.3M+119.6% | 8.78M-40.7% | 14.8M+98.3% | 7.46M+0.6% | 7.42M+44.2% | |
| Change in payables | -69.0K+99.3% | -9.61M-238.1% | 6.96M+261.2% | -4.32M-178.1% | 5.53M+322.3% | |
| Other operating activities | 0.00-100.0% | 83.0K-74.1% | 320K | — | — | |
| -696K-114.3% | 4.88M+181.3% | -6.00M-117.4% | 34.5M-64.8% | 98.0M+457.5% | ||
| Capital expenditure | — | — | — | — | 1.08M+187.8% | |
| Free cash flow | — | — | — | — | -96.6M-19.4% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchases of investments | 0.00-100.0% | 34.5M-21.2% | 43.7M | 0.00-100.0% | 43.0M-57.7% | |
| Sales/maturities of investments | 0.00-100.0% | 40.2M+0.6% | 40.0M+14.3% | 35.0M-66.2% | 104M+38.6% | |
| 11.4M-68.5% | 36.2M+2342.3% | -1.61M-101.3% | 127M+367.8% | 27.2M-78.4% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00-100.0% | 146M | 0.00-100.0% | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00-100.0% | 43.5M | 0.00-100.0% | |
| Common stock issued | 0.00 | 0.00 | 0.00-100.0% | 30.0M+11.1% | 27.0M-59.0% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | — | — | 0.00 | 0.00+100.0% | -3.00K+86.4% | |
| Net change in cash | 39.3M+866.1% | 4.07M+107.4% | -54.6M-192.5% | 59.0M+99.0% | 29.7M+64.1% | |
| Interest paid | 27.1M+0.6% | 26.9M-2.7% | 27.7M+155.0% | 10.9M+48.9% | 7.29M+60.1% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.35B+159.4% | 522M+60.8% | 325M+79.5% | 181M-50.6% | 366M+24.4% | |
| P/E | 2443.3× | — | — | — | — | |
| P/S | 4.6×+80.5% | 2.6×+20.9% | 2.1×+15.8% | 1.8×-75.1% | 7.4×-49.4% | |
| P/B | 98.9× | — | 84.0×+2455.8% | 3.3×-14.5% | 3.8×-55.9% | |
| Earnings yield | 0.04% | — | — | — | — | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
One company, more than one SEC registrant: these statements were filed by Xeris Pharmaceuticals Inc until Oct 5, 2021 and by Xeris Biopharma Holdings, Inc. since.
About this data
Source: XERS’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all XERS filings on SEC EDGAR → Not investment advice.